Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721653 | 0.91 | KCNN4 (0.34) | KCNN4PTPN1USP2RAB9ACYP1A1 | |
| SCHEMBL20603805 | 0.79 | KCNN4 (0.32) | KCNN4USP2RAB9ACYP1A1CYP1B1 | |
| SCHEMBL4785402 | 0.78 | KCNN4 (0.37) | KCNN4PTPN1USP2RAB9ACYP3A4 | |
| SCHEMBL1722405 | 0.74 | KCNN4 (0.39) | KCNN4USP2RAB9ACYP1A1CYP1B1 | |
| SCHEMBL20603608 | 0.74 | KCNN4 (0.34) | KCNN4USP2RAB9ACYP1A1CYP1B1 | |
| SCHEMBL15736923 | 0.74 | IDO1 (0.41) | KCNN4USP2RAB9ACYP1A1CYP1B1 | |
| SCHEMBL7813623 | 0.72 | CYP3A4 (0.43) | SIRT2PTPN1USP2RAB9ACYP3A4 | |
| SCHEMBL26633679 | 0.72 | LMNA (0.43) | KCNN4RAB9ACYP3A4 | |
| SCHEMBL9721848 | 0.72 | KCNN4 (0.39) | KCNN4PTPN1RAB9ACYP1A1CYP1B1 | |
| SCHEMBL10159619 | 0.71 | TSHR (0.46) | KCNN4PTPN1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014782-A1 | Novel n-(heterobicycloalkanes)-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| EP-1496058-A1 | Novel N-(heterobicycloalkanes)-substituted Indoles or heteroderivatives thereof | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014782-A1 | Novel n-(heterobicycloalkanes)-substituted indoles-or heteroderivatives thereof | CCR3, CCR1, CCRL2 | SIRT2 3982/4885KCNN4 2067/4885PTPN1 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.